Brandon Aubrey, Peter Miller, Timothy Graubert, Yi-Bin Chen, Rohiverth Guarecuco, Amir Fathi, Robert Hasserjian, Andrew Brunner. "A mutational grouping involving SRSF2, TET2, ASXL1, RUNX1, and STAG2 identifies patients with lower-risk myelodysplastic syndrome who benefit from higher-risk treatment strategies." Blood, 2025. doi:10.1182/blood-2025-2086